JP2012523438A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523438A5
JP2012523438A5 JP2012504929A JP2012504929A JP2012523438A5 JP 2012523438 A5 JP2012523438 A5 JP 2012523438A5 JP 2012504929 A JP2012504929 A JP 2012504929A JP 2012504929 A JP2012504929 A JP 2012504929A JP 2012523438 A5 JP2012523438 A5 JP 2012523438A5
Authority
JP
Japan
Prior art keywords
par
p1i3pal
agent
signaling activity
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030783 external-priority patent/WO2010118435A2/en
Publication of JP2012523438A publication Critical patent/JP2012523438A/ja
Publication of JP2012523438A5 publication Critical patent/JP2012523438A5/ja
Pending legal-status Critical Current

Links

JP2012504929A 2009-04-10 2010-04-12 メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化 Pending JP2012523438A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16835309P 2009-04-10 2009-04-10
US16836009P 2009-04-10 2009-04-10
US61/168,353 2009-04-10
US61/168,360 2009-04-10
PCT/US2010/030783 WO2010118435A2 (en) 2009-04-10 2010-04-12 Par-1 activation by metalloproteinase-1 (mmp-1)

Publications (2)

Publication Number Publication Date
JP2012523438A JP2012523438A (ja) 2012-10-04
JP2012523438A5 true JP2012523438A5 (https=) 2013-05-30

Family

ID=42936908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504929A Pending JP2012523438A (ja) 2009-04-10 2010-04-12 メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化

Country Status (7)

Country Link
US (3) US20120121706A1 (https=)
EP (3) EP2416799B1 (https=)
JP (1) JP2012523438A (https=)
AU (1) AU2010233089B2 (https=)
CA (1) CA2758322C (https=)
DE (1) DE202010018378U1 (https=)
WO (1) WO2010118435A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745347B2 (en) 2010-12-30 2017-08-29 Hadasit Medical Research Services And Development Ltd. PAR1 and PAR2 c-tail peptides and peptide mimetics
EP2606828B1 (en) * 2011-12-20 2018-04-11 Angioclinic AG Hyaluronic acid and its use for treating venous insufficiency and varicose veins
EP2681209B1 (en) * 2011-03-02 2018-05-09 Aquilus Pharmaceuticals, Inc Compounds and methods for the treatment of pain and other disorders
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2013183725A1 (ja) * 2012-06-06 2013-12-12 国立大学法人九州大学 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US9789209B2 (en) * 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015107139A1 (en) * 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
WO2016205062A1 (en) * 2015-06-15 2016-12-22 Shifa Biomedical Corporation Antithrombotic therapies
CN106551944A (zh) * 2015-09-25 2017-04-05 南开大学 四环素类衍生物作为par-1抑制剂的用途
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP7257333B2 (ja) * 2017-12-28 2023-04-13 株式会社カネカ 細胞凝集抑制剤
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
WO2020172113A1 (en) * 2019-02-18 2020-08-27 Lankenau Institute For Medical Research Scar reducing wound closure materials
US11419809B2 (en) 2019-06-27 2022-08-23 L'oreal Hair treatment compositions and methods for treating hair
KR102612229B1 (ko) * 2021-05-21 2023-12-08 가천대학교 산학협력단 N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물
US20230011767A1 (en) * 2021-07-09 2023-01-12 Boston Scientific Scimed, Inc. Direct oral anticoagulant-eluting medical device

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (https=) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3784701A (en) 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5525348A (en) 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
ES2069833T3 (es) 1990-12-03 1995-05-16 Celltech Ltd Derivados peptidilicos.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
CZ288436B6 (en) 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20050020607A1 (en) 1999-05-03 2005-01-27 Newton Roger Schofield Statin-MMP inhibitor combinations
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
EP2348047A1 (en) * 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
JP4469467B2 (ja) * 2000-06-29 2010-05-26 帝人株式会社 細胞増殖抑制剤
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US20050120392A1 (en) 2002-02-28 2005-06-02 Rubinstein Amy L. Transgenic zebrafish models for thrombosis
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
AU2004213050B2 (en) * 2003-02-20 2010-09-09 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US20050025705A1 (en) 2003-07-22 2005-02-03 Xinkang Wang Thrombosis animal models and their use in drug discovery and development
US7550444B2 (en) 2004-03-26 2009-06-23 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
EP1879552B1 (en) 2005-03-14 2016-02-17 Biotegra, Inc. Drug delivery compositions comprising a polyelectrolyte complex within a polymeric matrix
CA2843097C (en) * 2005-05-24 2015-10-27 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
US20080125354A1 (en) 2005-11-21 2008-05-29 Florida Atlantic University Selective inhibition of matrix metalloproteinases
US7888483B2 (en) 2006-07-18 2011-02-15 Irm Llc Antagonists of protease activated receptor-1 (PAR1)
JP4861115B2 (ja) * 2006-09-28 2012-01-25 サントリーホールディングス株式会社 ラベル、ラベルの製造方法、ラベルの線剥離強度の経時安定化方法、及び容器
US7838232B2 (en) * 2006-10-19 2010-11-23 Auburn University CaIDAG-GEF1 gene mutations associated with thrombopathy in canines
US9719191B2 (en) 2006-11-29 2017-08-01 The Research Foundation For The State University Of New York Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008118320A1 (en) 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US8383156B2 (en) 2007-04-30 2013-02-26 Cordis Corporation Coating for a medical device having an anti-thrombotic conjugate
US20090018646A1 (en) 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate
JP5483023B2 (ja) * 2008-03-27 2014-05-07 国立大学法人東北大学 がん細胞運動およびがん細胞浸潤抑制剤
WO2010119455A2 (en) * 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2012523438A5 (https=)
US20200384062A1 (en) Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
EP2605790B1 (en) Intranasal delivery of cell permeant therapeutics
WO2020060401A2 (en) Bioactive peptides derived from snakes
KR20180037185A (ko) 광범위의 항감염성 펩티드
WO2013082045A1 (en) Netrin loop peptide mimetics and uses thereof
EP1468085B1 (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
US9617325B2 (en) Treatment of IgE-mediated disease
CN107428811A (zh) 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A‑β‑物类的肽
US11439693B2 (en) Vasoconstrictive and antibacterial combination treatment for rosacea
US12016899B2 (en) Compositions comprising Sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
US12384818B2 (en) Cyclin-dependent kinase 5 (CDK5) inhibitory peptides
JP2023094736A (ja) 疼痛治療薬
US20130040886A1 (en) Peptides and Methods for Inhibiting G alpha Protein Signaling
WO2006006954A3 (en) Modified fusion peptides derived from a p53 domain against malignant and/or transformed mammalian cells
AU2003205658A1 (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis